New hope for babies with severe epilepsy: early access to fenfluramine
NCT ID NCT06598449
First seen May 17, 2026 · Last updated May 28, 2026 · Updated 5 times
Summary
This study is for children aged 12 to 23 months with Dravet syndrome, a severe genetic epilepsy that causes long seizures often triggered by fever. The drug fenfluramine is already approved for children 2 years and older and has been shown to greatly reduce seizures. This expanded access program aims to give younger children the same treatment while carefully monitoring safety. Only 5 children will take part, and doctors must provide a statement of potential benefit before enrollment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRAVET SYNDROME (DS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital Colorado
RECRUITINGAurora, Colorado, 80045, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.